JP2000507574A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507574A5
JP2000507574A5 JP1997535252A JP53525297A JP2000507574A5 JP 2000507574 A5 JP2000507574 A5 JP 2000507574A5 JP 1997535252 A JP1997535252 A JP 1997535252A JP 53525297 A JP53525297 A JP 53525297A JP 2000507574 A5 JP2000507574 A5 JP 2000507574A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997535252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507574A (ja
Filing date
Publication date
Priority claimed from US08/626,524 external-priority patent/US5837829A/en
Application filed filed Critical
Publication of JP2000507574A publication Critical patent/JP2000507574A/ja
Publication of JP2000507574A5 publication Critical patent/JP2000507574A5/ja
Withdrawn legal-status Critical Current

Links

JP9535252A 1996-04-02 1997-02-06 9―オキシムシリルエリトロマイシンa誘導体 Withdrawn JP2000507574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/626,524 US5837829A (en) 1996-04-02 1996-04-02 9-oximesilyl erythromycin a derivatives
US08/626,524 1996-04-02
PCT/US1997/001955 WO1997036913A1 (en) 1996-04-02 1997-02-06 9-oximesilyl erythromycin a derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007100369A Division JP2007224035A (ja) 1996-04-02 2007-04-06 9―オキシムシリルエリトロマイシンa誘導体

Publications (2)

Publication Number Publication Date
JP2000507574A JP2000507574A (ja) 2000-06-20
JP2000507574A5 true JP2000507574A5 (cg-RX-API-DMAC7.html) 2004-11-25

Family

ID=24510750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9535252A Withdrawn JP2000507574A (ja) 1996-04-02 1997-02-06 9―オキシムシリルエリトロマイシンa誘導体
JP2007100369A Pending JP2007224035A (ja) 1996-04-02 2007-04-06 9―オキシムシリルエリトロマイシンa誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007100369A Pending JP2007224035A (ja) 1996-04-02 2007-04-06 9―オキシムシリルエリトロマイシンa誘導体

Country Status (10)

Country Link
US (1) US5837829A (cg-RX-API-DMAC7.html)
EP (1) EP0891371B1 (cg-RX-API-DMAC7.html)
JP (2) JP2000507574A (cg-RX-API-DMAC7.html)
AT (1) ATE256138T1 (cg-RX-API-DMAC7.html)
CA (1) CA2250771C (cg-RX-API-DMAC7.html)
DE (1) DE69726714T2 (cg-RX-API-DMAC7.html)
DK (1) DK0891371T3 (cg-RX-API-DMAC7.html)
ES (1) ES2212808T3 (cg-RX-API-DMAC7.html)
PT (1) PT891371E (cg-RX-API-DMAC7.html)
WO (1) WO1997036913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004574A1 (en) 1996-07-29 1998-02-05 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2274799A (en) * 1997-12-22 1999-07-12 Biochemie S.A. Intermediates in macrolide production
KR100283990B1 (ko) * 1998-12-29 2001-03-02 민경윤 에리스로마이신 a 유도체 및 그의 제조방법
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
ES2244491T3 (es) * 1999-12-16 2005-12-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de polimorfos de claritromicina y nuevo polimorfo iv.
HRP20020572A2 (en) 2000-01-11 2005-04-30 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
ES2242668T3 (es) * 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de forma ii.
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) * 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC7.html)
JP2000501771A5 (cg-RX-API-DMAC7.html)
JP2000501599A5 (cg-RX-API-DMAC7.html)
JP2000501018A5 (cg-RX-API-DMAC7.html)
JP2000500076A5 (cg-RX-API-DMAC7.html)
JP2000501324A5 (cg-RX-API-DMAC7.html)
JP2000500055A5 (cg-RX-API-DMAC7.html)
JP2000502472A5 (cg-RX-API-DMAC7.html)
JP2000501825A5 (cg-RX-API-DMAC7.html)
JP2000501338A5 (cg-RX-API-DMAC7.html)
JP2000500874A5 (cg-RX-API-DMAC7.html)
JP2000502485A5 (cg-RX-API-DMAC7.html)
JP2000502425A5 (cg-RX-API-DMAC7.html)
JP2000502568A5 (cg-RX-API-DMAC7.html)
JP2000501774A5 (cg-RX-API-DMAC7.html)
JP2000500912A5 (cg-RX-API-DMAC7.html)
JP2000502570A5 (cg-RX-API-DMAC7.html)
JP2000501876A5 (cg-RX-API-DMAC7.html)
JP2000507574A5 (cg-RX-API-DMAC7.html)
JP2000501744A5 (cg-RX-API-DMAC7.html)
JP2000501229A5 (cg-RX-API-DMAC7.html)
JP2000500857A5 (cg-RX-API-DMAC7.html)
JP2000502316A5 (cg-RX-API-DMAC7.html)
JP2000502714A5 (cg-RX-API-DMAC7.html)
JP2000501569A5 (cg-RX-API-DMAC7.html)